Market Research Report
Europe Active Pharmaceutical Ingredients Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||819214|
|Published||Content info||93 Pages
Delivery time: 2-3 business days
|Europe Active Pharmaceutical Ingredients Market Forecast 2019-2027|
|Published: April 8, 2019||Content info: 93 Pages||
The pharmaceutical drug industry across the world is growing by leaps and bounds at present and is currently valued in billions approximately. The coveted companies in the market design the required drugs which predominantly contains the carrier substances and the active chemical substances that work in treating the condition known as the 'Active Pharmaceutical Ingredients' or API in short.
The Europe market for active pharmaceutical ingredients is on an exceptional upsurge in recent years since the region includes the developed countries in the likes of Germany, France, UK, etc. The regional market is expected to have an escalated growth, quantified by Inkwood Research as per the market analysis, to be around 5.75% CAGR by the end of 2027. The forecasting period is considered to be from 2019 to 2027, and 2018 is considered to be the base year for the market analysis.
The major economies that influence the market growth for APIs in the Europe region are the United Kingdom, France, Germany, Italy, Spain and the remaining countries collectively constituting the Rest of Europe regional segment.
In the United Kingdom, the presence of highly established healthcare infrastructure coupled with the high rate of cancer prevalence among the patient pool are the key driving factors for the API market. According to the Cancer Research United Kingdom, there are more than XX thousands of new cancer cases in the UK every year, which has escalated the adoption of the cancer drugs turbulently in the country.
Aurobindo Pharma, Lonza Group AG, Bayer AG, Novartis, Sun Pharmaceuticals Industries, Ltd., Merck & Co., Inc., Albemarle Corporation, Teva Pharmaceutical Industries, Ltd., Cipla, Mylan N.V., Dr. Reddy's Laboratories, Abbvie, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, and Eli Lilly and Company are the major companies mentioned in the report.